Try our mobile app

Switch to company model in classical logic    *

General information

Country: DENMARK

Sector: Biotechnology

Genmab A/S operates as a biotechnology company. The Company specializes in development of antibody therapeutics for the treatment of cancer. Genmab serves customers worldwide.
Website: genmab.com



Growth: Good revenue growth rate 31.6%, there is slowdown compared to average historical growth rates 51.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +50.2%. On average the margin is improving unsteadily. Gross margin is low, 0.0%. In the last quarter the company did not beat the estimated EPS, -92.2%. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$1.34 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -8.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 8.6% higher than minimum and 41.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.1x by EV / Sales multiple , the company can be 50.7% overvalued

Key Financials (Download financials)

Ticker: GMAB
Share price, USD:  (+1.3%)28.7
year average price 34.19  


year start price 40.99 2023-04-22

max close price 42.37 2023-05-22

min close price 26.43 2024-02-13

current price 28.70 2024-04-20
Common stocks: 653 836 087

Dividend Yield:  0.0%
FCF Yield LTM: -8.1%
EV / LTM EBITDA: 24.6x
EV / EBITDA annualized: 12.3x
Last revenue growth (y/y):  31.6%
Last growth of EBITDA (y/y):  175.4%
Historical revenue growth:  51.0%
Historical growth of EBITDA:  98.2%
EV / Sales: 12.4x
Margin (EBITDA LTM / Revenue): 50.2%
Fundamental value created in LTM:
Market Cap ($m): 18 765
Net Debt ($m): -1 223
EV (Enterprise Value): 17 542
Price to Book: 4.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-03GeekWire

Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal

2024-04-03Investopedia

Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio

2024-04-03Reuters

Denmark's Genmab to acquire ProfoundBio for $1.8 billion

2024-01-19Zacks Investment Research

Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

2024-01-11Seeking Alpha

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

2024-01-09Zacks Investment Research

GMAB or TECH: Which Is the Better Value Stock Right Now?

2023-09-05Market Watch

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

2023-09-04Reuters

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

2023-08-30Seeking Alpha

Genmab Is Down To Attractive Levels

2023-08-28GlobeNewsWire

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GMAB GMAB GMAB GMAB GMAB GMAB
reportedCurrency DKK DKK DKK DKK DKK DKK
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-14 2023-11-07 2023-08-03 2023-05-10 2022-12-31 2022-09-30
acceptedDate 2024-02-14 12:30:45 2023-11-07 11:12:38 2023-08-03 11:16:46 2023-05-10 11:23:53 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 4 678M 4 744M 4 198M 2 854M 5 227M 4 087M
costOfRevenue 126M 100M 0 0 0 0
grossProfit 4 552M 4 644M 4 198M 2 854M 5 227M 4 087M
grossProfitRatio 0.973 0.979 1.000 1.000 1.000 1.000
researchAndDevelopmentExpenses 1 948M 2 088M 1 853M 1 741M 1 641M 1 486M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 934M 839M 848M 676M 921M 670M
otherExpenses 0 0 0 0 0 0
operatingExpenses 2 882M 2 927M 2 701M 2 417M 2 562M 2 156M
costAndExpenses 3 008M 3 027M 2 701M 2 417M 2 562M 2 156M
interestIncome 295M 243M 209M 192M 140M 97M
interestExpense 6M 8M 7M 6M 5M 6M
depreciationAndAmortization 295M 243M 209M 192M -1 998M 1 347M
ebitda 1 965M 1 960M 1 706M 629M 2 805M 2 028M
ebitdaratio 0.420 0.413 0.406 0.220 0.537 0.496
operatingIncome 1 670M 1 717M 1 497M 437M 4 803M 681M
operatingIncomeRatio 0.357 0.362 0.357 0.153 0.919 0.167
totalOtherIncomeExpensesNet -744M 750M 24M -151M -4 141M 2 591M
incomeBeforeTax 926M 2 702M 1 723M 286M 662M 3 272M
incomeBeforeTaxRatio 0.198 0.570 0.410 0.100 0.127 0.801
incomeTaxExpense 286M 573M 366M 60M 78M 690M
netIncome 640M 2 129M 1 357M 226M 584M 2 582M
netIncomeRatio 0.137 0.449 0.323 0.079 0.112 0.632
eps 9.800 32.600 2.080 0.350 0.890 3.960
epsdiluted 9.670 32.320 2.060 0.340 0.890 3.920
weightedAverageShsOut 65M 65M 652M 660M 653M 653M
weightedAverageShsOutDil 66M 66M 658M 660M 659M 659M
link Link Link Link Link
finalLink Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GMAB GMAB GMAB GMAB GMAB GMAB
reportedCurrency DKK DKK DKK USD DKK DKK
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-14 2023-11-07 2023-08-03 2023-05-10 2022-12-31 2022-09-30
acceptedDate 2024-02-14 12:30:45 2023-11-07 11:12:38 2023-08-03 11:16:46 2023-05-10 11:23:53 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 14 867M 14 273M 10 874M 12 288M 9 893M 10 377M
shortTermInvestments 13 268M 13 252M 14 010M 12 256M 12 431M 13 411M
cashAndShortTermInvestments 28 135M 27 525M 24 884M 24 544M 22 324M 23 788M
netReceivables 4 947M 5 432M 4 814M 3 687M 6 053M 4 951M
inventory 57M 70M 51M 0 0 0
otherCurrentAssets 0 0 0 0 0 0
totalCurrentAssets 33 139M 33 027M 29 749M 28 231M 28 377M 28 739M
propertyPlantEquipmentNet 1 641M 1 651M 1 634M 1 596M 1 322M 1 289M
goodwill 0 0 0 0 0 0
intangibleAssets 0 115M 0 0 146M 0
goodwillAndIntangibleAssets 101M 115M 129M 132M 146M 200M
longTermInvestments 196M 156M 183M 140M 133M 155M
taxAssets 212M 252M 252M 252M 252M 264M
otherNonCurrentAssets 0 37M 31M 43M 48M 39M
totalNonCurrentAssets 2 150M 2 211M 2 229M 2 163M 1 901M 1 947M
otherAssets 0 0 0 0 0 0
totalAssets 35 289M 35 238M 31 978M 30 394M 30 278M 30 686M
accountPayables 2 307M 2 341M 0 0 0 0
shortTermDebt 90M 83M 82M 89M 74M 79M
taxPayables 54M 445M 0 0 0 948M
deferredRevenue 33M 33M 33M 33M 33M 33M
otherCurrentLiabilities 54M 445M 1 878M 1 833M 1 716M 2 876M
totalCurrentLiabilities 2 484M 2 902M 1 993M 1 955M 1 823M 2 988M
longTermDebt 680M 710M 721M 740M 523M 550M
deferredRevenueNonCurrent 480M 480M 480M 480M 480M 480M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 35M 34M 29M 29M 11M 929M
totalNonCurrentLiabilities 1 195M 1 224M 1 230M 1 249M 1 014M 1 041M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 680M 793M 803M 829M 597M 629M
totalLiabilities 3 679M 4 126M 3 223M 3 204M 2 837M 4 029M
preferredStock 0 0 0 0 0 0
commonStock 66M 66M 66M 66M 66M 66M
retainedEarnings 19 023M 18 452M 16 165M 14 666M 14 968M 14 299M
accumulatedOtherComprehensiveIncomeLoss 60M 142M 112M 117M 98M 151M
othertotalStockholdersEquity 12 461M 12 452M 12 412M 12 341M 12 309M 12 141M
totalStockholdersEquity 31 610M 31 112M 28 755M 27 190M 27 441M 26 657M
totalEquity 31 610M 31 112M 28 755M 27 190M 27 441M 26 657M
totalLiabilitiesAndStockholdersEquity 35 289M 35 238M 31 978M 30 394M 30 278M 30 686M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 35 289M 35 238M 31 978M 30 394M 30 278M 30 686M
totalInvestments 13 464M 13 408M 14 193M 12 396M 12 564M 13 566M
totalDebt 770M 793M 803M 829M 597M 629M
netDebt -14 097M -13 480M -10 071M -11 459M -9 296M -9 748M
link Link Link Link Link
finalLink Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol GMAB GMAB GMAB GMAB GMAB GMAB
reportedCurrency DKK DKK DKK DKK DKK DKK
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-14 2023-11-07 2023-08-03 2023-05-10 2022-12-31 2022-09-30
acceptedDate 2024-02-14 12:30:45 2023-11-07 11:12:38 2023-08-03 11:16:46 2023-05-10 11:23:53 2022-12-30 19:00:00 2022-09-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 640M 2 702M 1 723M 286M 662M 3 272M
depreciationAndAmortization 0 22M 0 0 0 0
deferredIncomeTax 0 -184M 0 0 0 0
stockBasedCompensation 0 162M 0 0 0 0
changeInWorkingCapital 158M -137M -1 496M 2 837M -1 476M -275M
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 0
otherWorkingCapital 158M -137M 0 0 0 0
otherNonCashItems 874M -528M 209M 112M 1 212M -1 029M
netCashProvidedByOperatingActivities 1 672M 2 037M 436M 3 235M 398M 1 968M
investmentsInPropertyPlantAndEquipment -67M -98M -107M -104M -110M -82M
acquisitionsNet 0 -1 106M 10M 0 0 0
purchasesOfInvestments -2 508M -1 272M -4 251M -2 876M -2 430M -3 185M
salesMaturitiesOfInvestments 2 133M 2 378M 2 523M 2 967M 2 404M 1 885M
otherInvestingActivites 0 1 106M -10M 0 0 0
netCashUsedForInvestingActivites -442M 1 008M -1 835M -13M -136M -1 382M
debtRepayment -25M -16M -29M -21M -26M -17M
commonStockIssued 9M 40M 0 0 0 0
commonStockRepurchased 0 -4M -21M -543M 0 -697M
dividendsPaid 0 -36M 0 0 0 0
otherFinancingActivites -6M 36M 57M -47M 157M 72M
netCashUsedProvidedByFinancingActivities -22M 20M 7M -611M 131M -642M
effectOfForexChangesOnCash -614M 334M -22M -216M -877M 617M
netChangeInCash 594M 3 399M -1 414M 2 395M -484M 561M
cashAtEndOfPeriod 14 867M 14 273M 10 874M 12 288M 9 893M 10 377M
cashAtBeginningOfPeriod 14 273M 10 874M 12 288M 9 893M 10 377M 9 816M
operatingCashFlow 1 672M 2 037M 436M 3 235M 398M 1 968M
capitalExpenditure -67M -98M -107M -104M -110M -82M
freeCashFlow 1 605M 1 939M 329M 3 131M 288M 1 886M
link Link Link Link Link
finalLink Link Link Link Link

Earning call transcript

2023 q4
2024-02-14 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-14 16:41 ET
Genmab Announces Initiation of Share Buy-Back Program
2024-02-14 16:02 ET
Genmab Publishes 2023 Annual Report
2024-02-02 11:45 ET
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
2023-12-09 17:00 ET
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
2023-11-27 12:00 ET
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
2023-11-08 16:09 ET
Major Shareholder Announcement
2023-11-07 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2023
2023-11-02 13:05 ET
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
2023-10-17 10:22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
2023-09-25 11:45 ET
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-09-25 11:45 ET
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-09-25 09:55 ET
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2023-09-04 19:00 ET
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
2023-08-03 15:01 ET
Genmab Announces Financial Results for the First Half of 2023
2023-08-03 15:01 ET
Genmab Announces Financial Results for the First Half of 2023
2023-07-27 22:01 ET
Genmab Updates 2023 Financial Guidance
2023-07-27 22:01 ET
Genmab Updates 2023 Financial Guidance
2023-07-21 08:30 ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-21 08:30 ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-21 08:30 ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-07-20 10:22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
2023-07-20 10:22 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
2023-06-27 22:50 ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-27 22:49 ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-27 22:49 ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
2023-06-22 11:00 ET
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
2023-06-22 11:00 ET
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
2023-06-20 18:45 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2023-06-09 07:01 ET
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
2023-06-09 07:01 ET
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
2023-06-08 21:22 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2023-06-06 06:00 ET
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-31 12:15 ET
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
2023-05-25 21:10 ET
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
2023-05-25 21:10 ET
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
2023-05-23 19:14 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2023-05-19 16:38 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-05-19 16:33 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-05-19 16:33 ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
2023-05-10 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2023
2023-05-10 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2023
2023-04-24 08:39 ET
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
2023-04-24 08:39 ET
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
2023-04-20 23:45 ET
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
2023-04-20 23:45 ET
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
2023-04-18 10:25 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
2023-04-18 10:25 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
2023-04-17 06:00 ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-04-17 06:00 ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-04-17 06:00 ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
2023-04-03 14:12 ET
Completion of share buy-back program
2023-03-29 20:19 ET
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
2023-03-29 20:10 ET
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2023-03-29 13:53 ET
Passing of Genmab A/S’ Annual General Meeting
2023-03-28 06:00 ET
Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
2023-03-27 13:00 ET
Transactions in connection with share buy-back program
2023-03-13 11:18 ET
Transactions in connection with share buy-back program
2023-02-28 19:54 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2023-02-27 16:21 ET
Transactions in connection with share buy-back program
2023-02-24 20:32 ET
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2023-02-23 11:00 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2023-02-22 20:45 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2023-02-22 18:11 ET
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
2023-02-22 16:12 ET
Genmab Announces Initiation of Share Buy-Back Program
2023-02-22 16:12 ET
Genmab Announces Initiation of Share Buy-Back Program
2023-02-22 16:01 ET
Genmab Publishes 2022 Annual Report
2023-02-22 16:01 ET
Genmab Publishes 2022 Annual Report
2023-01-24 19:00 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2023-01-24 11:27 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
2023-01-24 11:27 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
2023-01-19 16:00 ET
Correction to Company Announcement No. 1 of January 3, 2023
2023-01-03 17:31 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2023-01-02 12:56 ET
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 12:00 ET
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-12-21 12:00 ET
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-12-13 20:05 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-12-13 19:58 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-12-12 13:23 ET
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
2022-12-11 22:30 ET
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
2022-12-11 22:30 ET
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
2022-11-23 19:56 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-11-21 19:44 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-11-21 19:39 ET
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
2022-11-21 13:00 ET
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-11-21 13:00 ET
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-11-15 18:54 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-11-14 17:30 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-11-10 13:27 ET
Genmab to Present at Jefferies London Healthcare Conference
2022-11-09 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2022
2022-11-09 16:01 ET
Genmab Announces Financial Results for the First Nine Months of 2022
2022-11-03 16:45 ET
Genmab Improves Its 2022 Financial Guidance
2022-11-03 16:45 ET
Genmab Improves Its 2022 Financial Guidance
2022-11-03 13:01 ET
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
2022-11-03 13:01 ET
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
2022-10-28 12:45 ET
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
2022-10-28 12:45 ET
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
2022-10-18 10:35 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
2022-10-18 10:35 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
2022-10-05 19:56 ET
Major Shareholder Announcement
2022-10-05 19:56 ET
Major Shareholder Announcement
2022-09-27 16:43 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-09-20 19:20 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-09-06 14:53 ET
Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-01 16:27 ET
Completion of share buy-back program
2022-08-29 09:04 ET
Transactions in connection with share buy-back program
2022-08-16 18:26 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-08-16 18:22 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-08-15 07:42 ET
Transactions in connection with share buy-back program
2022-08-10 15:01 ET
Genmab Announces Financial Results for the First Half of 2022
2022-08-10 15:01 ET
Genmab Announces Financial Results for the First Half of 2022
2022-08-08 16:33 ET
Genmab Improves Its 2022 Financial Guidance
2022-08-08 16:33 ET
Genmab Improves Its 2022 Financial Guidance
2022-08-05 10:45 ET
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
2022-08-02 18:46 ET
Major Shareholder Announcement
2022-07-25 11:49 ET
Transactions in connection with share buy-back program
2022-07-20 17:03 ET
Major Shareholder Announcement
2022-07-20 17:03 ET
Major Shareholder Announcement
2022-07-19 10:33 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
2022-07-19 10:33 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
2022-07-18 14:05 ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-07-18 14:01 ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-07-18 14:01 ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2022-07-11 15:28 ET
Major Shareholder Announcement
2022-07-11 08:50 ET
Transactions in connection with share buy-back program
2022-07-05 18:05 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-07-01 14:14 ET
Major Shareholder Announcement
2022-07-01 14:14 ET
Major Shareholder Announcement
2022-06-30 18:24 ET
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-06-30 18:24 ET
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
2022-06-27 08:09 ET
Transactions in connection with share buy-back program
2022-06-23 15:55 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-06-20 14:35 ET
Major Shareholder Announcement
2022-06-20 14:35 ET
Major Shareholder Announcement
2022-06-17 14:38 ET
Genmab Announces Initiation of Share Buy-Back Program
2022-06-11 12:45 ET
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
2022-06-11 12:45 ET
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium
2022-06-09 21:17 ET
Genmab Commences New Arbitration Under License Agreement With Janssen
2022-06-09 21:17 ET
Genmab Commences New Arbitration Under License Agreement With Janssen
2022-06-09 18:57 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-06-08 18:32 ET
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-06 15:00 ET
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
2022-06-01 16:21 ET
Major Shareholder Announcement
2022-06-01 16:21 ET
Major Shareholder Announcement
2022-05-26 21:00 ET
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-26 21:00 ET
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-17 18:32 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-05-12 14:00 ET
Genmab Announces Multiple Abstracts to be Presented at the European Hematology Association (EHA) Annual Congress
2022-05-12 14:00 ET
Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress
2022-05-11 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2022
2022-05-11 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2022
2022-04-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
2022-04-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
2022-04-13 22:53 ET
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-13 21:26 ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-13 21:25 ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-13 21:25 ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
2022-04-07 23:44 ET
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
2022-04-07 23:44 ET
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
2022-03-29 18:34 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-03-29 18:28 ET
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-03-29 13:15 ET
Passing of Genmab A/S’ Annual General Meeting
2022-03-14 12:47 ET
Genmab Announces the Nomination of a New Member of the Company’s Board of Directors
2022-03-08 12:31 ET
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
2022-03-08 12:30 ET
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
2022-03-01 14:14 ET
Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer
2022-02-25 21:19 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-02-25 21:13 ET
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2022-02-24 15:00 ET
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
2022-02-24 11:01 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2022-02-24 11:01 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2022-02-22 19:11 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2022-02-16 19:14 ET
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
2022-02-16 16:00 ET
Genmab Publishes 2021 Annual Report
2022-02-16 16:00 ET
Genmab Publishes 2021 Annual Report
2022-01-26 13:44 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-01-25 20:30 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2022-01-25 11:30 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
2022-01-25 11:30 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
2022-01-04 14:00 ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
2022-01-04 14:00 ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
2022-01-04 14:00 ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
2022-01-03 23:38 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2022-01-03 12:19 ET
Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-14 18:06 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-12-13 08:28 ET
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base
2021-11-22 20:59 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-11-22 20:53 ET
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
2021-11-16 18:11 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-11-10 16:00 ET
Genmab Announces Financial Results for the First Nine Months of 2021
2021-11-10 16:00 ET
Genmab Announces Financial Results for the First Nine Months of 2021
2021-11-04 20:24 ET
Genmab Improves its 2021 Financial Guidance
2021-11-04 20:24 ET
Genmab Improves its 2021 Financial Guidance
2021-11-04 13:06 ET
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
2021-11-04 13:05 ET
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
2021-11-03 14:18 ET
Genmab to Present at Jefferies Virtual London Healthcare Conference
2021-10-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
2021-10-19 10:29 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
2021-10-15 17:05 ET
Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
2021-10-07 18:55 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2021-10-01 12:00 ET
Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
2021-09-21 18:22 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-09-21 18:22 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-09-20 21:00 ET
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
2021-09-20 21:00 ET
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
2021-09-19 15:30 ET
Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
2021-09-09 11:00 ET
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
2021-09-09 11:00 ET
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
2021-09-09 11:00 ET
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
2021-08-27 08:42 ET
Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-17 18:51 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-08-11 15:01 ET
Genmab Announces Financial Results for the First Half of 2021
2021-08-11 15:01 ET
Genmab Announces Financial Results for the First Half of 2021
2021-07-21 16:58 ET
Major Shareholder Announcement
2021-07-21 16:58 ET
Major Shareholder Announcement
2021-07-21 10:31 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
2021-07-21 10:31 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
2021-07-06 18:04 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-07-01 07:42 ET
Completion of share buy-back program
2021-06-22 20:16 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2021-06-22 14:12 ET
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-06-22 14:12 ET
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-06-21 07:46 ET
Transactions in connection with share buy-back program
2021-06-10 13:53 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-06-07 08:01 ET
Transactions in connection with share buy-back program
2021-06-02 12:00 ET
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
2021-06-01 10:27 ET
Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-25 07:57 ET
Transactions in connection with share buy-back program
2021-05-21 19:03 ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
2021-05-21 13:08 ET
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-05-21 13:08 ET
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-05-19 21:01 ET
Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
2021-05-19 10:41 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-05-11 18:43 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-05-10 07:55 ET
Transactions in connection with share buy-back program
2021-05-05 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2021
2021-05-05 15:01 ET
Genmab Announces Financial Results for the First Quarter of 2021
2021-05-03 18:58 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-04-26 07:18 ET
Transactions in connection with share buy-back program
2021-04-20 10:34 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
2021-04-20 10:34 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
2021-04-13 20:44 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-04-13 20:39 ET
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab
2021-04-13 13:26 ET
Passing of Genmab A/S’ Annual General Meeting
2021-04-12 07:54 ET
Transactions in connection with share buy-back program
2021-04-09 20:00 ET
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
2021-04-09 20:00 ET
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
2021-03-30 05:21 ET
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2021-03-30 05:21 ET
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2021-03-29 15:19 ET
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
2021-03-29 07:12 ET
Transactions in connection with share buy-back program
2021-03-15 08:46 ET
Transactions in connection with share buy-back program
2021-03-10 22:37 ET
Genmab Announces Preclinical Data to be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
2021-03-09 09:14 ET
Notice to Convene the Annual General Meeting of Genmab A/S
2021-03-07 11:39 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-03-02 20:26 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2021-03-01 09:03 ET
Transactions in connection with share buy-back program
2021-02-26 21:08 ET
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
2021-02-25 19:53 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-02-25 19:53 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-02-23 16:05 ET
Genmab announces initiation of share buy-back program
2021-02-23 16:05 ET
Genmab announces initiation of share buy-back program
2021-02-23 16:00 ET
Genmab Publishes 2020 Annual Report
2021-02-23 16:00 ET
Genmab Publishes 2020 Annual Report
2021-02-22 13:00 ET
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
2021-02-22 13:00 ET
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
2021-02-10 21:05 ET
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2021-02-10 21:05 ET
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2021-01-29 17:10 ET
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
2021-01-29 17:10 ET
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
2021-01-28 21:56 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2021-01-27 14:50 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-01-26 11:45 ET
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
2021-01-26 11:45 ET
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
2021-01-15 19:17 ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-01-15 19:17 ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
2021-01-13 14:20 ET
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
2021-01-13 14:20 ET
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
2021-01-06 15:15 ET
Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-05 01:26 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2021-01-04 19:00 ET
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
2020-12-15 22:09 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2020-12-15 22:01 ET
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
2020-12-03 16:41 ET
Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer
2020-11-24 15:40 ET
Genmab Announces Enapotamab Vedotin Update
2020-11-24 15:40 ET
Genmab Announces Enapotamab Vedotin Update
2020-11-19 12:00 ET
ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease
2020-11-10 19:57 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2020-11-10 12:59 ET
Genmab to Present at Jefferies Virtual London Healthcare Conference
2020-11-05 13:39 ET
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
2020-11-05 13:38 ET
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
2020-11-05 11:26 ET
Genmab Announces that Janssen has Submitted a Type II Variation Application to the European Medicines Agency for use of Subcutaneous DARZALEX® (daratumumab) in Patients with Light-chain (AL) amyloidosis
2020-11-04 16:04 ET
Genmab Announces Financial Results for the First Nine Months of 2020
2020-11-04 16:04 ET
Genmab Announces Financial Results for the First Nine Months of 2020
2020-11-04 15:13 ET
Genmab Announces Data to be Presented at 2020 ASH Annual Meeting
2020-10-30 11:15 ET
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
2020-10-30 11:15 ET
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
2020-10-21 20:48 ET
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
2020-10-21 20:48 ET
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
2020-10-15 13:02 ET
Genmab to Host Capital Markets Day
2020-10-13 10:42 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
2020-10-13 10:41 ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
2020-10-07 21:13 ET
Grant of Restricted Stock Units and Warrants to Employees in Genmab
2020-09-29 19:48 ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
2020-09-29 19:36 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2020-09-22 21:04 ET
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
2020-09-22 21:04 ET
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
2020-09-21 14:20 ET
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
2020-09-21 14:20 ET
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
2020-09-10 12:06 ET
Genmab Announces that Janssen has Submitted a Supplemental Biologics License Application to U.S. FDA for use of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in Patients with Light-chain (AL) Amyloidosis
2020-09-09 12:47 ET
Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
2020-08-26 22:05 ET
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
2020-08-20 20:40 ET
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-08-20 20:40 ET
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-08-20 20:06 ET
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
2020-08-20 20:06 ET
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
2020-08-20 17:33 ET
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2020-08-20 17:33 ET
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
2020-08-18 19:40 ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
2020-08-12 15:23 ET
Genmab Announces Financial Results for the First Half of 2020
2020-08-12 15:23 ET
Genmab Announces Financial Results for the First Half of 2020
2020-07-31 19:38 ET
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-07-31 19:38 ET
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
2020-07-20 15:57 ET
Major Shareholder Announcement
2020-07-20 15:57 ET
Major Shareholder Announcement
2020-07-16 10:43 ET
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
2020-07-16 10:43 ET
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
2020-07-07 11:01 ET
Major Shareholder Announcement
2020-07-03 07:51 ET
Major Shareholder Announcement
2020-07-03 07:51 ET
Major Shareholder Announcement

SEC forms

Show financial reports only

SEC form 6
2024-02-14 00:00 ET
Genmab published news for 2023 q4
SEC form 6
2024-02-14 00:00 ET
Genmab published news for 2023 q4
SEC form 6
2024-02-14 00:00 ET
Genmab published news for 2023 q4
SEC form 6
2023-11-08 12:24 ET
Genmab published news for 2023 q3
SEC form 6
2023-11-07 11:12 ET
Genmab reported for 2023 q3
SEC form 6
2023-10-17 08:22 ET
Genmab published news for 2023 q3
SEC form 6
2023-10-05 10:35 ET
Genmab published news for 2023 q3
SEC form 6
2023-09-28 16:15 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-25 08:53 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-13 09:59 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-12 15:05 ET
Genmab published news for 2023 q2
SEC form 6
2023-09-05 09:12 ET
Genmab published news for 2023 q2
SEC form 6
2023-08-03 11:16 ET
Genmab published news for 2023 q2
SEC form 6
2023-07-27 18:15 ET
Genmab published news for 2023 q2
SEC form 6
2023-07-21 09:08 ET
Genmab published news for 2023 q2
SEC form 6
2023-07-20 09:00 ET
Genmab published news for 2023 q2
SEC form 6
2023-06-27 18:54 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-21 11:18 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-20 15:58 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-20 12:57 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-08 17:27 ET
Genmab published news for 2023 q1
SEC form 6
2023-06-01 16:24 ET
Genmab published news for 2023 q1
SEC form 6
2023-05-31 09:44 ET
Genmab published news for 2023 q1
SEC form 6
2023-05-24 10:46 ET
Genmab published news for 2023 q1
SEC form 6
2023-05-23 15:26 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-18 10:20 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-06 16:52 ET
Genmab reported for 2023 q1
SEC form 6
2023-04-03 17:18 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-03 11:14 ET
Genmab published news for 2023 q1
SEC form 6
2023-04-03 09:46 ET
Genmab published news for 2023 q1
SEC form 6
2023-03-29 16:32 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-29 10:05 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-27 10:58 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-20 11:10 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-13 11:53 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-06 12:14 ET
Genmab published news for 2022 q4
SEC form 6
2023-03-01 10:47 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-28 16:32 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-28 10:49 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-27 13:46 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-24 16:11 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-23 13:46 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 15:51 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 12:55 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 11:48 ET
Genmab published news for 2022 q4
SEC form 6
2023-02-22 00:00 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-30 11:39 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-24 14:33 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-24 08:49 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-19 11:55 ET
Genmab published news for 2022 q4
SEC form 6
2023-01-03 12:55 ET
Genmab published news for 2022 q4
SEC form 6
2022-12-14 15:50 ET
Genmab published news for 2022 q3
SEC form 6
2022-12-14 09:02 ET
Genmab published news for 2022 q3
SEC form 6
2022-12-13 15:54 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-29 10:33 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-23 15:14 ET
Genmab reported for 2022 q3
SEC form 6
2022-11-21 14:55 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-16 10:19 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-15 14:05 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-14 13:52 ET
Genmab published news for 2022 q3
SEC form 6
2022-11-09 11:31 ET
Genmab reported for 2022 q3
SEC form 6
2022-11-03 13:55 ET
Genmab published news for 2022 q3
SEC form 6
2022-10-18 08:48 ET
Genmab published news for 2022 q3
SEC form 6
2022-10-05 16:11 ET
Genmab published news for 2022 q3
SEC form 6
2022-09-28 09:21 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-27 12:51 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-26 09:30 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-20 15:31 ET
Genmab published news for 2022 q2
SEC form 6
2022-09-01 12:41 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-29 09:38 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-24 15:04 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-22 09:05 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-17 13:33 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-17 10:48 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-16 14:40 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-15 09:14 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-10 00:00 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-08 12:49 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-08 08:29 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-02 15:08 ET
Genmab published news for 2022 q2
SEC form 6
2022-08-01 10:42 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-25 08:40 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-20 14:02 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-19 08:14 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-18 11:08 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-18 09:27 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-11 12:10 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-11 10:35 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-06 09:06 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-05 14:11 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-05 10:29 ET
Genmab published news for 2022 q2
SEC form 6
2022-07-01 12:23 ET
Genmab published news for 2022 q2
SEC form 6
2022-06-30 14:32 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-27 10:24 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-23 12:02 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-21 08:33 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-17 11:01 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-16 09:06 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-09 17:22 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-09 15:19 ET
Genmab published news for 2022 q1
SEC form 6
2022-06-01 12:37 ET
Genmab published news for 2022 q1
SEC form 6
2022-05-18 10:52 ET
Genmab published news for 2022 q1
SEC form 6
2022-05-17 14:39 ET
Genmab published news for 2022 q1
SEC form 6
2022-05-11 11:24 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-19 08:08 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-13 17:28 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-07 20:09 ET
Genmab published news for 2022 q1
SEC form 6
2022-04-07 09:23 ET
Genmab published news for 2022 q1
SEC form 6
2022-03-29 14:58 ET
Genmab published news for 2021 q4
SEC form 6
2022-03-29 09:37 ET
Genmab published news for 2021 q4
SEC form 6
2022-03-14 09:58 ET
Genmab published news for 2021 q4
SEC form 6
2022-03-09 10:14 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-25 16:35 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-24 09:15 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-23 11:28 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-22 14:21 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-16 13:56 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-16 00:00 ET
Genmab published news for 2021 q4
SEC form 6
2022-02-03 10:18 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-26 09:45 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-25 15:43 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-25 08:39 ET
Genmab published news for 2021 q4
SEC form 6
2022-01-03 18:46 ET
Genmab published news for 2021 q4
SEC form 6
2021-12-15 08:40 ET
Genmab published news for 2021 q3
SEC form 6
2021-12-14 13:23 ET
Genmab published news for 2021 q3
SEC form 6
2021-12-01 10:07 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-22 16:09 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-17 12:02 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-16 13:22 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-10 12:01 ET
Genmab published news for 2021 q3
SEC form 6
2021-11-04 17:23 ET
Genmab published news for 2021 q3
SEC form 6
2021-10-19 10:28 ET
Genmab published news for 2021 q3
SEC form 6
2021-10-15 10:27 ET
Genmab published news for 2021 q3
SEC form 6
2021-10-07 15:04 ET
Genmab published news for 2021 q3
SEC form 6
2021-09-22 08:53 ET
Genmab published news for 2021 q2
SEC form 6
2021-09-21 14:35 ET
Genmab published news for 2021 q2
SEC form 6
2021-09-20 17:16 ET
Genmab published news for 2021 q2
SEC form 6
2021-08-18 13:13 ET
Genmab published news for 2021 q2
SEC form 6
2021-08-17 15:03 ET
Genmab published news for 2021 q2
SEC form 6
2021-08-11 00:00 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-21 14:13 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-21 08:39 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-07 09:01 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-06 14:17 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-01 09:54 ET
Genmab published news for 2021 q2
SEC form 6
2021-07-01 09:34 ET
Genmab published news for 2021 q2
SEC form 6
2021-06-28 09:59 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-22 16:47 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-22 11:22 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-21 09:35 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-15 21:52 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-14 09:17 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-10 11:05 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-07 10:46 ET
Genmab published news for 2021 q1
SEC form 6
2021-06-01 11:04 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-25 10:13 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-21 09:49 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-21 09:28 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-19 09:30 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-17 11:32 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-12 16:14 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-12 12:44 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-11 15:36 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-10 10:25 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-07 16:33 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-05 12:54 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-03 15:16 ET
Genmab published news for 2021 q1
SEC form 6
2021-05-03 13:02 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-26 17:00 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-26 11:39 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-20 10:47 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-19 10:10 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-15 15:15 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-13 16:54 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-13 09:53 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-12 09:47 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-09 16:32 ET
Genmab published news for 2021 q1
SEC form 6
2021-04-06 12:15 ET
Genmab published news for 2021 q1
SEC form 6
2021-03-30 09:54 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-29 11:07 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-29 10:28 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-22 14:19 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-15 13:55 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-09 09:25 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-08 11:49 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-08 10:25 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-03 11:42 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-02 16:09 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-02 14:47 ET
Genmab published news for 2020 q4
SEC form 6
2021-03-01 10:14 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-26 16:24 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-25 16:40 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-23 14:30 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-23 12:38 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-22 09:53 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-10 17:05 ET
Genmab published news for 2020 q4
SEC form 6
2021-02-05 10:54 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-29 14:39 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-28 17:26 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-27 11:06 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-26 10:14 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-15 15:23 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-13 09:59 ET
Genmab published news for 2020 q4
SEC form 6
2021-01-04 21:11 ET
Genmab published news for 2020 q4
SEC form 6
2020-12-21 10:25 ET
Genmab published news for 2020 q3
SEC form 6
2020-12-15 17:17 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-24 11:59 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-12 09:54 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-10 15:04 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-05 11:06 ET
Genmab published news for 2020 q3
SEC form 6
2020-11-04 11:48 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-21 17:06 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-15 11:09 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-14 16:54 ET
Genmab published news for 2020 q3
SEC form 6
2020-10-07 17:15 ET
Genmab published news for 2020 q3
SEC form 6
2020-09-30 14:06 ET
Genmab published news for 2020 q2
SEC form 6
2020-09-30 10:49 ET
Genmab published news for 2020 q2
SEC form 6
2020-09-29 17:49 ET
Genmab published news for 2020 q2